Biggest Gainers in FY12 To-Date Getting Smacked This Week (ARNA) (VVUS) (LCC)
Tweet Send to a Friend
Up)
The following is a brief list of stocks that have had the best performance year-to-date, but have been getting hit this week. Numbers are just a snapshot and subject to change as the markets see fit.
Three of the following names have been making rapid moves on weight-management approvals and positive FDA committee comments (Orexigen, VIVUS, and Arena). Those names are all down on the session today as well.
US Airways was getting pumped over a possible takeover of AMR Corp. (OTCBB: AAMRQ), but recent quarterly results from AMR have some speculating on whether or not the deal will go through.
Threshold got a kick in the pants in February after announcing a collaboration agreement with Merck KGaA over TH-302. Positive Phase 2b results for TH-302 kept the momentum going in February, though shares have been flat since early April.
Pharmacyclics has just been like the "smooth jazz" station on your radio dial: easy, breezy, riding the wave. The pharma made gains this year on ibrutinib data, which have been positive.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Three of the following names have been making rapid moves on weight-management approvals and positive FDA committee comments (Orexigen, VIVUS, and Arena). Those names are all down on the session today as well.
US Airways was getting pumped over a possible takeover of AMR Corp. (OTCBB: AAMRQ), but recent quarterly results from AMR have some speculating on whether or not the deal will go through.
Threshold got a kick in the pants in February after announcing a collaboration agreement with Merck KGaA over TH-302. Positive Phase 2b results for TH-302 kept the momentum going in February, though shares have been flat since early April.
Pharmacyclics has just been like the "smooth jazz" station on your radio dial: easy, breezy, riding the wave. The pharma made gains this year on ibrutinib data, which have been positive.
- Threshold Pharmaceuticals (Nasdaq: THLD) - up 485 percent on year, down 7.8 percent for the week.
- Arena Pharmaceuticals (Nasdaq: ARNA) - up 416 percent for the year, down 9.1 percent for the week.
- Orexigen (Nasdaq: OREX) - up 293 percent on the year, down 4.4 percent from Monday.
- Pharmacyclics Inc. (Nasdaq: PCYC) - up 235 percent for the year, down 8.8 percent for the week.
- VIVUS (Nasdaq: VVUS) - up 164 percent for the year, down 7.0 percent for the week.
- US Airways Group (NYSE: LCC) - up 147 percent on the year, down 10.5 percent for the week.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Fannie Mae, Freddie Mac Surge as Seriously Delinquent Rate Falls Below 3%
- UPDATE: Chile regulators stopped build, imposed sanctions on Barrick Gold (ABX)
- Highway Holdings (HIHO) Halted Again on Circuit Breaker; Last Up 80%
Create E-mail Alert Related Categories
Insiders' Blog, Momentum MoversRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
